Compare DexCom, Inc. (DXCM) vs Global X Defense Tech ETF (SHLD) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

SHLD trades at $59.71, down 0.85% today, with a bearish technical signal from moving averages and ADX indicators. The ETF offers exposure to global defense technology firms amid rising military budgets. Key support is at $59, with resistance at $61. Recent news highlights its role in the defense rearmament theme, though it faces competition from other defense ETFs.

Outlook is mixed: geopolitical tensions and increased defense spending support long-term growth, but technical weakness and competitive ETF landscape pose near-term risks. Investors should weigh the sector's defensive characteristics against current bearish momentum and valuation comparisons with peers like XAR and ITA.